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Abstract
Despite the established role of SDHB/SDHA immunohistochemistry as a
valuable tool to identify patients at risk for familial succinate dehydrogenase-
related pheochromocytoma/paraganglioma syndromes, the reproducibility of
the assessment methods has not as yet been determined. The aim of
this study was to investigate interobserver variability among seven expert
endocrine pathologists using a web-based virtual microscopy approach in a
large multicenter pheochromocytoma/paraganglioma cohort (n=351): (1) 73 SDH
mutated, (2) 105 non-SDH mutated, (3) 128 samples without identified SDH-
x mutations, and (4) 45 with incomplete SDH molecular genetic analysis.
Substantial agreement among all the reviewers was observed either with a
two-tiered classification (SDHB κ=0.7338; SDHA κ=0.6707) or a three-tiered
classification approach (SDHB κ=0.6543; SDHA κ=0.7516). Consensus was
achieved in 315 cases (89.74%) for SDHB immunohistochemistry and in 348
cases (99.15%) for SDHA immunohistochemistry. A...
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Despite the established role of SDHB/SDHA immunohistochemistry as a valuable tool to identify patients at risk
for familial succinate dehydrogenase-related pheochromocytoma/paraganglioma syndromes, the reproducibility
of the assessment methods has not as yet been determined. The aim of this study was to investigate
interobserver variability among seven expert endocrine pathologists using a web-based virtual microscopy
approach in a large multicenter pheochromocytoma/paraganglioma cohort (n= 351): (1) 73 SDH mutated, (2) 105
non-SDHmutated, (3) 128 samples without identified SDH-xmutations, and (4) 45 with incomplete SDHmolecular
genetic analysis. Substantial agreement among all the reviewers was observed either with a two-tiered
classification (SDHB κ= 0.7338; SDHA κ= 0.6707) or a three-tiered classification approach (SDHB κ= 0.6543;
SDHA κ= 0.7516). Consensus was achieved in 315 cases (89.74%) for SDHB immunohistochemistry and in 348
cases (99.15%) for SDHA immunohistochemistry. Among the concordant cases, 62 of 69 (~90%) SDHB-/C-/D-/
AF2-mutated cases displayed SDHB immunonegativity and SDHA immunopositivity, 3 of 4 (75%) with SDHA
mutations showed loss of SDHA/SDHB protein expression, whereas 98 of 105 (93%) non-SDH-x-mutated
counterparts demonstrated retention of SDHA/SDHB protein expression. Two SDHD-mutated extra-adrenal
paragangliomas were scored as SDHB immunopositive, whereas 9 of 128 (7%) tumors without identified SDH-x
mutations, 6 of 37 (~16%) VHL-mutated, as well as 1 of 21 (~5%) NF1-mutated tumors were evaluated as SDHB
immunonegative. Although 14 out of those 16 SDHB-immunonegative cases were nonmetastatic, an overall
significant correlation between SDHB immunonegativity and malignancy was observed (P=0.00019). We
conclude that SDHB/SDHA immunohistochemistry is a reliable tool to identify patients with SDH-xmutations with
an additional value in the assessment of genetic variants of unknown significance. If SDH molecular genetic
analysis fails to detect a mutation in SDHB-immunonegative tumor, SDHC promoter methylation and/or VHL/NF1
testing with the use of targeted next-generation sequencing is advisable.
Modern Pathology advance online publication, 27 February 2015; doi:10.1038/modpathol.2015.41
Pheochromocytomas and paragangliomas are neural
crest-derived neuroendocrine tumors arising from
the adrenal medulla and sympathetic/parasympa-
thetic paraganglia, respectively.1 These carry the
highest degree of heritability among human neo-
plasms. Germline and/or somatic mutations of at
least 18 genes (NF1, RET, VHL, SDHA, SDHB, SDHC,
SDHD, SDHAF2, TMEM127, MAX, HIF2A, KIF1B,
PHD1, PHD2/EGLN1, FH, HRAS, BAP1, and MEN1)
are involved in development of the tumors, with
∼40% harboring a germline mutation and an addi-
tional 25–30% a somatic mutation.2–4
Familial succinate dehydrogenase-related pheo-
chromocytoma/paraganglioma syndromes are
caused by SDHA, SDHB, SDHC, SDHD, and SDHAF2
(collectively SDH-x) mutations and inherited as
autosomal dominant traits.4 These syndromes pre-
dispose not only to pheochromocytomas/paragan-
gliomas, but also to gastrointestinal stromal tumors,
renal cell carcinomas, and pituitary adenomas.5–7 In
the vast majority of succinate dehydrogenase-
associated tumors, there is also loss of SDHB and/
or SDHA protein expression that can be detected by
immunohistochemistry.5–41 In particular, SDHB-,
SDHC-, and SDHD-mutated tumors display SDHB
immunonegativity but SDHA immunoreactivity,
whereas SDHA-mutated tumors show negativity for
both SDHB and SDHA immunostainings. Gastroin-
testinal stromal tumors and paragangliomas, asso-
ciated with Carney triad (the syndromic but
nonhereditary association of gastrointestinal stromal
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tumor, paraganglioma, pulmonary chondroma, adre-
nocortical adenoma, and esophageal leiomyoma),4
show negative staining for SDHB in the absence of
SDH-x mutations.29,40 There is provisional evidence
that Carney triad-related tumors display somatic
hypermethylation of the SDHC promoter locus,42
and therefore negative staining for SDHB may also
identify these cases not found by conventional
molecular testing.
As loss of SDHB/ SDHA expression is
predictive of an underlying SDH-x germline
mutation,8,10,11,17,21–24,29,34,39 the role of SDHB/
SDHA immunohistochemistry has been underlined
as a supplementary approach in molecular genetic
testing especially for pheochromocytomas and
paragangliomas.8,10,11 As Sanger or targeted next-
generation sequencing analysis of all pheochromo-
cytoma/paraganglioma susceptibility genes is labor
intensive and/or requires clinical molecular diag-
nostic laboratories,43–45 it might be prudent to use
immunohistochemistry to identify patients with
succinate dehydrogenase-related pheochromocy-
toma/paraganglioma syndromes. In addition, the
presence of an SDHBmutation is one of the strongest
predictors for both metastasis and subsequently poor
outcome in pheochromocytomas/paragangliomas.4
In this context, it has been proposed that a combina-
tion of the GAPP (grading system for adrenal
phaeochromocytoma and paraganglioma) and SDHB
immunohistochemistry might be a valuable aid in
the prediction of metastatic disease,46 further neces-
sitating correct interpretation of SDHB/SDHA
immunostainings.
Given the high prevalence of unsuspected heredi-
tary disease, false-positive as well as false-negative
evaluations of SDHB/SDHA immunostainings can
lead to failure to identify pheochromocytoma/para-
ganglioma-affected individuals at increased risk for
succinate dehydrogenase-related neoplasia, incor-
rect interpretation of the pathogenicity of genetic
variants of uncertain significance, and inappropriate
genetic testing. Because studies addressing the issue
of interobserver variation for SDHB/SDHA immuno-
histochemistry in pheochromocytomas/paraganglio-
mas are lacking, we assessed interobserver agreement
among practicing expert endocrine pathologists
through virtual microscopy in a large multicenter,
multinational cohort of genetically well-charac-
terized tumors. Accordingly, we examined the validity
of SDHB/SDHA immunohistochemistry to identify
patients with succinate dehydrogenase-related
pheochromocytomas/paragangliomas and of SDHB
immunohistochemistry as a marker of malignancy.
Materials and methods
Case Selection
A total of 351 paraganglionic tumors from 333
patients of median age 46 years (ranging from 5.5
to 84 years; 56% females) were retrieved from 15
specialized centers from Europe, United States, and
Australia: (1) Université catholique de Louvain,
Brussels, Belgium (95 samples from 84 patients),
(2) Hôpital Européen Georges Pompidou, Paris,
France (68 samples from 67 patients), (3) University
of Florence, Florence, Italy (40 samples), (4) National
Institutes of Health (NIH), Bethesda, MD, USA
(24 samples), (5) Klinikum der Universität München,
Munich, Germany (20 samples), (6) Radboud
University Nijmegen Medical Center, Nijmegen,
The Netherlands (18 samples from 17 patients),
(7) Instituto Português de Oncologia de Lisboa
Francisco Gentil E.P.E., Lisbon, Portugal (15 samples
from 12 patients), (8) Hôpital Cochin, Paris, France
(13 samples), (9) Jagiellonian University Medical
College, Krakow, Poland (12 samples), (10) Tech-
nische Universität Dresden, Dresden, Germany
(11 samples), (11) San Luigi Gonzaga Hospital and
University of Turin, Turin, Italy (11 samples), (12)
Erasmus MC Cancer Institute, Rotterdam, The Neth-
erlands (10 samples from 8 patients), (13) University
of Sydney, Sydney, Australia (8 samples), (14)
Spanish National Cancer Research Centre (CNIO),
Madrid, Spain (5 samples), and (15) Hospital
Universitario San Cecilio, Granada, Spain (1 sample).
Clinical and genetic characteristics of these patients
are detailed in Supplementary Tables 1 and 2. Thirty
samples (30 out of 351; 8.54%) were considered
malignant (Supplementary Table 2) as primary
tumors and/or recurrences in the presence of meta-
static disease to sites where chromaffin tissue is not
normally found4 or as metastases themselves.
Out of 351 tumor samples, (1) 73 were SDH-x
mutated (39 SDHD, 24 SDHB, 4 SDHA, 4 SDHAF2,
and 2 SDHC), (2) 105 non-SDH-x mutated (37 VHL,
25 RET, 21 NF1, 8MAX, 6 HIF2A, 4 TMEM127, and 4
HRAS), (3) 128 wild-type cases (7 head and neck
paragangliomas, 13 extra-adrenal paragangliomas,
and 108 pheochromocytomas) that have been tested
negative for mutations and large deletions in the
SDH-x genes, and (4) 45 samples with incomplete
SDH-x molecular genetic analysis in terms of either
SDH-x genes or the techniques performed, that is,
Sanger sequencing and/or multiplex ligation-depen-
dent probe amplification. A total of 225 samples
were analyzed at least for 3 pheochromocytoma/
paraganglioma susceptibility genes with 129 and 30
harboring mutations at the germline and somatic
level, respectively (Supplementary Table 1). Based
on clinical grounds, 19 tumors were considered NF1,
RET, or VHL mutated (Supplementary Table 1).
None of these tumor samples have been previously
published elsewhere in terms of SDHB/SDHA
immunohistochemical investigation and all were
anonymously assessed according to the Proper
Secondary Use of Human Tissue code established
by the Dutch Federation of Medical Scientific
Societies (http://www.federa.org). Informed consent
was obtained for genetic analysis and access to
the clinical data in accordance with institutional
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guidelines. The Medical Ethical Committee of the
Erasmus MC approved the study.
SDHB/SDHA Immunohistochemistry
Each case was thoroughly reviewed and representa-
tive unstained glass slide(s) (n= 147) and/or for-
malin-fixed, paraffin-embedded block(s) (n=204)
were selected and further provided for immunohis-
tochemical analysis within a single research setting
(Department of Pathology, Erasmus MC Cancer
Institute, Rotterdam, The Netherlands) with the follow-
ing protocol. Slides and formalin-fixed, paraffin-
embedded whole-tissue sections of 4 μm thickness
were stained with commercially available antibodies:
(1) mouse monoclonal Ab14715 antibody (Mito-
sciences, Abcam, Cambridge, UK; 1:500 dilution)
against SDHA and (2) rabbit polyclonal HPA002868
antibody (Sigma-Aldrich, St Louis, MO, USA; 1:400
dilution) against SDHB on an automatic Ventana
Benchmark Ultra System (Ventana Medical Systems,
Tuscon, AZ, USA) using Ultraview DAB detection
system preceded by heat-induced epitope retrieval
with Ventana Cell Conditioning 1 (pH 8.4) at 97 °C
for 52 and 92min, respectively. Diaminobenzidine
was used as the chromogen.
Telepathology Application
High-resolution, whole-slide images were acquired
from 702 SDHB/SDHA immunostainings using a
NanoZoomer Digital Pathology System (Hamamatsu
Photonics KK, Japan) working at a resolution of
0.23 μm/pixel. The immunostainings were scanned
at × 40 magnification and automatically digitized in
their proprietary NanoZoomer Digital Pathology Image
file format. A quality control was subsequently set to
ensure good focus. Between August 2012 and
December 2013, digital files were consecutively
uploaded in six sets to a server at Erasmus MC through
the standard File transfer Protocol with URL http://
digimic.erasmusmc.nl/, enabling online worldwide
viewing through a virtual microscopy interface (Nano-
Zoomer Digital Pathology.view Viewer Software,
Hamamatsu Photonics KK).
Participants and Interpretation of Staining Results
Seven pathologists, including five who had pub-
lished on SDHB and/or SDHA immunohistochem-
ical assessments and two who had dealt with
endocrine pathology on diagnostic and research
grounds for many years (AJG, F van N, AST, FT,
MV, XM-G, and RRdeK), received: (1) a word file
detailing the context and the objectives of the project
along with an instructory panel of SDHB/SDHA
immunohistochemistry, (2) a Virtual Microscopy
(NanoZoomer Digital Pathology) Manual, (3) the
corresponding link providing access to the virtual
slides of the first set of tumors, and (4) a scoring list
to be completed during SDHB/SDHA immunohisto-
chemical evaluations.
All virtual slides were distributed online, reviewed
by each observer in a blinded manner without
knowledge of the corresponding clinicopathological
and genetic data or scores assigned by other
pathologists and scored as follows: (1) with regard
to SDHB immunohistochemistry: Positive as granu-
lar cytoplasmic staining displaying the same inten-
sity as internal positive control (endothelial cells,
sustentacular cells, lymphocytes); Negative as com-
pletely absent staining in the presence of an internal
positive control;Weak diffuse as a cytoplasmic blush
lacking definite granularity contrasting the strong
granular staining of internal positive control; Hetero-
geneous as granular cytoplasmic staining combined
with a cytoplasmic blush lacking definite granularity
or completely absent staining in the presence of an
internal positive control throughout the same slide;
Noninformative as completely absent staining in the
absence of an internal positive control; and (2) with
regard to SDHA immunohistochemistry: Positive as
granular cytoplasmic staining displaying the same
intensity as internal positive control (endothelial
cells, sustentacular cells, lymphocytes); Negative as
completely absent staining in the presence of an
internal positive control; Heterogeneous as granular
cytoplasmic staining combined with a cytoplasmic
blush lacking definite granularity or completely
absent staining in the presence of an internal positive
control throughout the same slide; Noninformative
as completely absent staining in the absence of an
internal positive control.
In an effort to simulate widespread adoption of the
scoring system as would occur in community
practice, no prescoring consensus meeting was
organized. In order to imitate clinical practice as
much as possible for SDHB/SDHA immuno-
histochemical interpretations, we selected a large
retrospective cohort comprising SDH-x- and non-
SDH-x-mutated paraganglionic tumors with and
without mutations in the remainder pheochromo-
cytoma/paraganglioma-associated genes.
Statistical Analysis
Interobserver agreement was assessed using κ statis-
tics; the strength of the former was evaluated with
criteria previously described by Landis and Koch.47
A κ-value of o0 indicates less than chance agreement,
o0.20 is regarded as slight agreement, 0.21–0.40 as
fair agreement, 0.41–0.60 as moderate agreement,
0.61–0.80 as substantial agreement, 0.81–0.99 as
almost perfect agreement, and 1 indicates perfect
agreement. A dichotomous classification was used
for the analysis of the pathologists’ evaluations
(negative/weak diffuse and positive) as well as a
three-tiered classification approach (negative/weak
diffuse, positive, and heterogeneous). Consensus was
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defined as agreement at least among five out of seven
pathologists reaching the same interpretation on
positive, negative/weak diffuse, heterogeneous, and
noninformative expression for SDHB/SDHA immu-
nohistochemistry. Discordant evaluation was
defined as at least three observers reporting different
SDHB/SDHA expression patterns on the same slide.
In order to capture the performance of SDHB
immunohistochemistry as a predictive tool, we
calculated Youden’s J statistic (Youden’s index) per
pathologist either in tumors harboring SDH-x muta-
tions vs non-SDH-x mutations or in SDH-x-mutated
tumors vs counterparts without identified SDH-x
mutations. We used Pearson’s χ2 test to associate (1)
SDHB IHC status with biological behavior (ie,
benignancy vs malignancy) taking into consideration
only concordant cases as well as excluding metas-
tases (n=7) and doubled samples (n=6)
(Supplementary Table 2), and (2) SDHD mutations
and weak diffuse pattern on SDHB immunohisto-
chemistry based on a consolidated call from at least
four observers. Two-sided P-values of o0.05 were
considered statistically significant. Statistical
analyses were performed using Analyse-it v2.26
(Analyse-it Software, Leeds, UK).
Results
The interobserver agreement following a two-tiered
classification approach (ie, positive and weak dif-
fuse/negative) ranged from moderate to almost
perfect for SDHB immunohistochemistry and from
fair to perfect for SDHA immunohistochemistry
(Table 1). With regard to SDHB immunohistochem-
istry, the highest agreement was reached between
observers 2 and 3 (κ=0.8593) and the lowest between
observers 4 and 7 (κ=0.5318), whereas regarding
SDHA immunohistochemistry, the highest agree-
ment was reached between observers 6 and 2/7
(κ=1.0000) and the lowest between observers 4 and 5
(κ=0.3542). All agreements were highly significant
(Po0.0001). Substantial agreement among all the
reviewers was observed either with a two-tiered
classification (SDHB κ=0.7338; SDHA κ=0.6707) or
a three-tiered classification approach (SDHB
κ=0.6543; SDHA κ=0.7516). Notably, observer 1 as
well as observers 3/4/5 did not score any slide as
heterogeneous pattern for SDHB and SDHA immu-
nohistochemistry respectively.
Consensus among pathologists was achieved in
348 cases (99.15%) for SDHA immunohistochemis-
try and in 315 cases (89.74%) for SDHB immuno-
histochemistry, respectively. Out of 69 tumor
samples with SDHB/SDHC/SDHD/SDHAF2 muta-
tions, 62 (89.85%) displayed SDHB immunonegativ-
ity and SDHA immunopositivity, whereas 3 of 4 with
SDHA mutations (75%) showed loss of SDHA/SDHB
protein expression (Figure 1). Two SDHD-mutated
extra-adrenal paragangliomas (c.274G4T p.Asp92Tyr
and c.405delC p.Phe136Leufs*32) were scored as
SDHB immunopositive by 5 observers and as
immunonegative (weak diffuse) by the other observers
(observers 2/5).
All tumors harboring RET, TMEM127, HIF2A, and
HRAS mutations, 31 of 37 VHL-mutated tumors
(83.7%), and 20 of 21 NF1 mutated-tumors (95.2%)
displayed retention of SDHB/SDHA expression
(Figure 2). Six benign VHL-mutated pheochromocy-
tomas (6 out of 37; ~ 16%) and one malignant NF1-
mutated extra-adrenal paraganglioma (1 out of 21;
~ 5%) were evaluated as SDHB immunonegative
(VHL: by all observers (3 cases), 6 observers (1 case),
and 5 observers (2 cases); NF1: by 6 observers (1
case)) in the absence of SDH-x mutations in four of
these cases (two examined at the germline, one at the
germline and somatic, and one at the somatic level).
Data on the exact mutations were available only
in four cases (VHL p.Ser80Asn, p.Arg161*,
p.Arg167Gln, and NF1 p.Trp561*).
In the absence of SDH-x mutations, 119 out of 128
paraganglionic tumors (93%) were scored as SDHB/
SDHA immunopositive, whereas the remainder (9
out of 128; 7%) as SDHB immunonegative/SDHA
immunopositive. Clinicopathological and genetic
data of the latter from four independent centers are
detailed in Table 2.
Discordant evaluations of SDHB immunohisto-
chemistry were reported in 5 tumors endowed with
SDH-x (SDHD/SDHB/SDHAF2) mutations, 11 VHL-
and 2 RET-mutated tumors, as well as 18 tumors
without identified SDH-xmutations, whereas of SDHA
immunohistochemistry concerned 2 SDH-x-mutated
tumors (SDHA-/SDHD-) and 1 NF1-mutated tumor.
Table 1 Interobserver agreement (κ-values) for SDHA (upper half) and SDHB (lower half) immunohistochemistry
Observer 1 Observer 2 Observer 3 Observer 4 Observer 5 Observer 6 Observer 7
Observer 1 — 0.7471 0.7471 0.4942 0.5944 0.8557 0.8557
Observer 2 0.7623 — 0.7471 0.4942 0.7972 1.0000 0.8557
Observer 3 0.8561 0.8593 — 0.4942 0.5387 0.8557 0.8557
Observer 4 0.6282 0.6508 0.6819 — 0.3542 0.5672 0.5672
Observer 5 0.7943 0.7998 0.8286 0.5981 — 0.6628 0.6628
Observer 6 0.7199 0.8021 0.7721 0.7276 0.7759 — 1.0000
Observer 7 0.8733 0.6476 0.7923 0.5318 0.6880 0.6621 —
All agreements Po0.0001.
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The classification of stainings as ‘noninformative’ and
‘heterogeneous’ represented the major reason for
SDHB/SDHA immunohistochemical discrepancies in
the SDH-x-mutated subgroup, whereas the ‘weak
diffuse’ category accounted largely for those in the
SDH-x-wild-type and VHL-mutated subsets.
The association between the predicted SDH
genetic status and SDHB immunohistochemistry
Figure 1 SDHA and SDHB immunohistochemistry in pheochromocytomas/paragangliomas endowed either with SDHA germline
mutation displaying loss of SDHA/SDHB protein expression or with SDHB, SDHC, SDHD, and SDHAF2 germline mutations exhibiting
loss of SDHB, but intact SDHA expression. Note the granular, cytoplasmic staining for SDHA/SDHB in normal cells of the intratumoral
fibrovascular network that serve as internal positive controls.
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was investigated for each observer. The sensitivity of
this approach, defined as the percentage of SDH-x
mutated tumors that are SDHB immunonegative,
ranged from 83.58 to 98.57% (mean 94.23%). The
specificity, defined as the percentage of either non-
SDH-x-mutated tumors or tumors without identified
SDH-x mutations that are SDHB immunopositive,
varied between 74.03 and 96.11% (mean 84.35%) as
well as 83.06 and 92.91% (mean 86.67%), respec-
tively. Observer 1 was the best predictor with a
Youden’s index of 0.880 and 0.860 (Table 3). A
significant correlation was observed between SDHB
immunonegativity and malignancy (P=0.00019). No
association could be shown between the SDHD
mutations and the weak diffuse pattern on SDHB
immunohistochemistry (P=0.1490).
Discussion
Immunohistochemistry has revolutionized the prac-
tice of endocrine pathology during the last decade. In
parallel with recent advances in molecular genetics,
immunohistochemistry has been shown to detect
various types of molecular alterations, that is, BRAF
V600E mutation in papillary thyroid carcinomas,48
PTEN mutations in various neoplastic thyroid
lesions,49 CTNNB1 mutations in cribriform-morular
variant of papillary thyroid carcinoma, undifferen-
tiated carcinomas of the thyroid gland and adreno-
cortical carcinomas,48,50,51 TP53mutations as well as
mutations in mismatch repair (MMR) genes such as
MLH1, MSH2, MSH6, and PMS2 in adrenocortical
carcinomas,51–53 HRPT2 mutations in parathyroid
carcinomas and hyperparathyroidism-jaw tumor
syndrome-related adenomas,48,54 PRKAR1A muta-
tions in Carney complex-associated tumors,55–57 and
SDH-, FH- as well as MAX deleterious-mutations in
pheochromocytomas/paragangliomas.8,10,11,58,59
Loss of SDHB protein expression is seen in
pheochromocytomas/paragangliomas either harbor-
ing a mutation in any of the SDH genes or with
somatic hypermethylation of the SDHC promoter
region,42 whereas loss of both SDHB and SDHA
immunoreactivity is demonstrated only in the con-
text of an SDHA mutation.8–20 In agreement with
previous studies,8,10,11,17–20 SDHB-/C-/D- and SDHA-
mutated tumors displayed the aforementioned
Figure 1 Continued.
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immunoexpression patterns with SDHAF2-mutated
counterparts showing SDHB immunonegativity and
SDHA immunopositivity. Notably, all tumors har-
boring RET, TMEM127, HIF2A, and HRAS mutations
displayed retention of SDHB/SDHA expression,
whereas six benign VHL-mutated pheochromocyto-
mas and one malignant NF1-mutated extra-adrenal
paraganglioma were evaluated as SDHB immuno-
negative. The latter contrasts previous observa-
tions in 37 pheochromocytomas/paragangliomas
Figure 2 Intact SDHB and SDHA protein expression in non-SDH-x-mutated paraganglionic tumors harboring germline or somatic VHL,
RET, NF1, TMEM127, MAX, EPAS1, and HRASmutations. Note the granular, cytoplasmic staining for SDHA/SDHB in normal cells of the
intratumoral fibrovascular network that serve as internal positive controls.
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and 14 pheochromocytomas endowed with VHL8,11
and NF1 mutations,8,10 respectively. By using a
mouse monoclonal (21A11) SDHB antibody at a
low concentration (1 in 1000), Gill et al10 suggested
that VHL-associated tumors could be classified
as negative or weak diffuse rather than positive
as demonstrated by a high concentration approach
of two SDHB antibodies.8 In accordance, loss of
SDHB protein expression has been recently
displayed in a subset of NF1-mutated paraganglionic
tumors (J Favier 2014, personal communication).
The remote possibility of a double mutant, poten-
tially explaining the SDHB immunonegativity by an
additional SDH-x mutation, was ruled out in four
of these seven cases occurring in the VHL- and
NF1-deficient setting.
To further expand earlier observations,8,11 9 of 128
(7%) tumors without identified SDH-x mutations
Figure 2 Continued.
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were evaluated as SDHB immunonegative (Table 2).
Van Nederveen et al8 and Castelblanco et al11
reported on 9 cases (6 out of 53; 11% and 3 out of
19; 15.7%) displaying loss of SDHB expression in the
absence of SDHB, SDHC, SDHD, VHL, or RET
mutation. Nevertheless, these studies lacked either
SDHA/SDHAF2 genetic testing8,11 or screening for
large-scale SDH-x deletions11 that may account for
higher percentages. Intriguingly, in the present
study, eight SDHB-immunonegative tumors were
nonmetastatic in the absence of SDH-x mutations
(Table 2), bearing a close resemblance to the Carney
triad-associated counterparts in terms of SDHB
immunohistochemistry and biologic behavior.4,29,60
Because somatic hypermethylation of SDHC was not
investigated, the possibility that the aforementioned
tumors represented cases of Carney triad could not
be assessed. Nevertheless, as shown herein, SDHB
immunohistochemical status overall is strongly
correlated with the clinical behavior of pheochro-
mocytoma/paraganglioma, further strengthening the
role of SDHB immunohistochemistry as a prognostic
marker.46,61
Our data reinforce the notion that immunohisto-
chemistry is a valid tool to identify patients at risk
for familial succinate dehydrogenase-related pheo-
chromocytoma/paraganglioma syndromes, although
occasionally this might be difficult even in a
specialized setting (Table 3). Exemplifying the latter,
two extra-adrenal paragangliomas with missense and
frameshift SDHD mutations were scored as SDHB
immunopositive by five observers. Similar discrep-
ancy has been previously reported for an extra-
adrenal paraganglioma harboring a nonsense SDHD
mutation (c.14G4A p.Trp5*) in a patient with
Carney Stratakis syndrome.31 Given that the patient
additionally developed an SDHB-immunonegative
gastrointestinal stromal tumor31 and that identical
Figure 2 Continued.
Table 2 Clinicopathological and genetic data of patients with SDHB-immunonegative paraganglionic tumors in the absence of SDH-x
mutations
Syndromic presentation Molecular genetic testing of PCC/PGL susceptibility genes a
Sample
code
Familial
PCC/
PGL history
Multiple
tumors
Age at
presentation Sex
Tumor
type Dignity SDHB SDHD SDHC SDHA SDHAF2 SDHAF1 VHL TMEM127 MAX
BEL 30 No No 43 F HN PGL B — — — — — ND — — —
BEL 67 No No 36 M HN PGL B — — — — — ND — — —
DR 11 No No 27 F HN PGL B — — — ND — ND ND — —
ITA 28 No No 73 F HN PGL B — — — — — ND — — —
DR 10b No Yes 33 F EA PGL B — — — — — — ND ND —
BEL 66 No No 15 F EA PGL M — — — — — ND — — —
BEL 116 No No 20 M PCC B — — — — — ND — — ND
ITA 48 No No 47 F PCC B — — — — — ND — — —
FR115c No No 23 M PCC B — — — — ND ND — — —
Abbreviations: B, benign; EA, extra-adrenal; F, female; HN, head and neck; M, male; M, malignant; ND, not done; PCC, pheochromocytoma; PGL,
paraganglioma.
aSDH-x genes have been tested both for point mutations and large deletions at the germline level with DR10 and ITA48 also investigated at the
somatic level.
bTested for FH at the germline and EPAS1 at the somatic level without any mutations subsequently detected.
cTested for RET mutations as well for SDH-x/VHL large deletions at the germline level without any mutations subsequently detected.
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missense and nonsense SDHD mutations in other
tumors have led to absence of SDHB expression,5,8 it
is possible that either the second hit in the SDHD
gene in the paraganglioma resulted in an inactive
succinate dehydrogenase complex with preservation
of antigenicity or that the interpretation was erro-
neous. Of note, every pathologist in the current study
missed at least one SDH-x-related tumor, and these
most frequently involved mutations in SDHD. This
suggests SDHD immunohistochemistry as a potential
complementary tool to SDHB immunohistochemis-
try to identify SDHD-mutated patients.62 Further
adding to those rare familial cases characterized by
disparity between molecular genetic aberrations of a
tumor suppressor gene and retention of protein
expression,63 one papillary renal cell carcinomas
arising in a patient with a germline missense SDHC
mutation (c.3G4A p.M1I) and harboring somatic
loss of heterozygosity of the SDHC locus paradoxi-
cally displayed SDHB immunopositivity.36 Taken
together, SDHB immunohistochemistry and SDH-x
genetic analysis should be viewed as complementary
tests. In cases of strong clinical suspicion, follow-up
mutational analysis should be considered despite
retention of SDHB expression.
The good level of reproducibility in the current
study may either reflect a high level of experience
with scoring SDHB/SDHA immunostainings among
expert endocrine pathologists or be attributable in
part to the fact that very precise scoring guidelines
were provided. Accordingly, it would be essential
to provide such guidelines in clinical reporting
templates64 as well as to guide development of
algorithms for computer-assisted diagnostics in a
digital pathology perspective. The classification of
stainings as ‘non-informative’ and ‘heterogeneous’
represented the major reason for SDHA/SDHB
immunohistochemical discrepancies in the SDH-x-
mutated subgroup, whereas the ‘weak diffuse’ cate-
gory accounted largely for inconsistencies in the
SDH-x-wild-type and VHL-mutated subsets. These
could be potentially ascribed to (1) technical varia-
bility owing to differences in fixation time, buffered
formalin concentrations, and/or age of the formalin-
fixed, paraffin-embedded blocks,10,11 (2) biological
variability, for example, reduced SDHB protein
levels in VHL-mutated paraganglionic tumors,65 or
even to (3–4) individual conceptions and experience
from specific staining protocols, as has been shown
with immunohistochemistry for MMR proteins.66
Technically suboptimal immunostainings were not
unexpectedly encountered given the fact that pro-
vided material was derived from several pathology
laboratories, each following their own fixation and
embedding protocols; highlighting the importance of
standardizing preanalytical variables in surgical
pathology specimens.67,68
In contrast to previous studies10,11 indicating a
stronger correlation of weak diffuse pattern with
SDHD mutations, we could not significantly rein-
force this particular association. Moreover, SDHB
and/or SDHA immunohistochemistry may not
always be an all-or-none phenomenon. In particular,
two SDHA- and SDHAF2-mutated tumors displayed
a heterogeneous expression pattern (Figures 3 and 4)
being consistent with previous observations con-
cerning SDHB immunohistochemistry in a pituitary
adenoma harboring an SDHD germline mutation.37
Along the same lines, heterogeneous expression
patterns have been reported both with MMR protein
immunohistochemistry in Lynch syndrome and
PTEN immunohistochemistry in Cowden syn-
drome.49,69,70 The biologic nature of heterogeneous
tumors in these genetic contexts is currently
Table 3 Associating predicted SDHB IHC status either with SDH-x-mutated vs non-SDH-x-mutated status (A) or with SDH-x-mutated vs
SDH-x-wild-type status (B)a
Observer 1 Observer 2 Observer 3 Observer 4 Observer 5 Observer 6 Observer 7
A
Sensitivity 95.71% 98.57% 94.44% 93.22% 98.57% 95.52% 83.58%
Specificity 92.30% 77.66% 90.00% 74.03% 82.35% 78.02% 96.11%
PPV 89.33% 75.00% 87.17% 67.07% 79.31% 76.19% 93.33%
NPV 96.96% 98.76% 95.74% 95.06% 98.82% 95.94% 90.00%
Pval Po0.0001 Po0.0001 Po0.0001 Po0.0001 Po0.0001 Po0.0001 Po0.0001
Youden’s index 0.880 0.762 0.844 0.672 0.809 0.735 0.796
B
Sensitivity 95.71% 98.57% 94.44% 93.22% 98.57% 95.52% 83.58%
Specificity 90.47% 83.06% 87.70% 84.55% 83.73% 84.21% 92.91%
PPV 84.81% 76.66% 81.92% 74.32% 77.52% 78.04% 86.15%
NPV 97.43% 99.03% 96.39% 96.29% 99.03% 96.96% 91.47%
Pval Po0.0001 Po0.0001 Po0.0001 Po0.0001 Po0.0001 Po0.0001 Po0.0001
Youden’s index 0.860 0.816 0.821 0.777 0.823 0.797 0.764
Abbreviations: Pval, P-value χ2 test; PPV, positive predictive value; NPV, negative predictive value.
Youden’s index is defined as sensitivity+specificity-1. The higher the Youden’s index, the better the prediction.
Sensitivity is defined as the percentage of SDH-x-mutated tumors that are SDHB immunonegative Specificity is defined as the percentage of non-
SDH-x-mutated tumors or tumors without identified SDH-x mutations that are SDHB immunopositive.
aHeterogeneous and noninformative scorings are excluded.
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unknown.37,49,69,70 Because of potential misinterpre-
tation of heterogeneous patterns for SDHB and/or
SDHA protein loss, SDH genetic testing is recom-
mended when confronted with such cases.
In addition to a comprehensive next-generation
sequencing-based strategy for the analysis of multi-
ple pheochromocytoma/paraganglioma susceptibil-
ity genes,43–45 several algorithms have been
proposed as a targeted approach to genetic testing
in clinical practice.8,71–74 In this rapidly expanding
field, the importance of assessing the pathogenicity
of a ‘variant of unknown significance’ has become a
major and complex problem facing diagnostic
laboratories. Our data further strengthen the role of
SDHB/SDHA immunohistochemistry in determining
the functionality of such variants, alone or in an
integrated approach with in silico analysis75,76
and/or western blot analysis, succinate dehydrogen-
ase enzymatic assay, and mass spectrometric-based
measurements of ratios of succinate/fumarate and
other metabolites.77–79
In the current study, we conclude that SDHB/
SDHA immunohistochemistry represents a reliable
tool to identify patients with SDH-x mutations with
an additional utility to evaluate the pathogenicity
of SDH variants of unknown significance in the
new next-generation sequencing era. A heteroge-
neous SDHB and/or SDHA immunoexpression pat-
tern has to be followed by SDH molecular genetic
testing, although a SDHB-immunonegative subset of
VHL- and NF1-mutated paraganglionic tumors chal-
lenges the issue of specificity for SDHB immunohis-
tochemistry. Hence, if SDH genetics fails to detect a
mutation in SDHB-immunonegative tumor, SDHC
promoter methylation and/or VHL/NF1 testing with
the use of targeted next-generation sequencing is
advisable. Our findings highlight the need for quality
assessment programs regarding not only standar-
dized staining protocols, but also SDHB/SDHA
immunohistochemical evaluation procedures. In a
prospective setting, with standardized tissue
fixation combined with a locally fine-tuned
Figure 3 An extra-adrenal paraganglioma harboring an SDHA (c.1534C4T, p.Arg512*) germline mutation, metastatic to a paraaortic
lymph node, displaying SDHB immunonegativity (a, c), but a heterogeneous staining pattern for SDHA (b, d–f): central area (d)
convincingly negative for SDHA, peripheral areas (f) convincingly positive for SDHA, and transitional zones (e) in between exhibiting cells
with intact SDHA expression intermingled with cells with absent SDHA expression. Three pathologists correctly classified this sample as
heterogeneous for SDHA, with the remainder four observers as positive for SDHA. Note the granular, cytoplasmic staining for SDHA/
SDHB in normal cells of the intratumoral fibrovascular network that serve as internal positive controls.
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immunohistochemical staining protocol, the sensi-
tivity and specificity of the SDHA/SDHB immuno-
histochemistry can be improved.
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